Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

Clinical Cancer Research

Volumn 13, Issue 8, 2007, Pages 2318-2322

  Mann, Bhupinder S ^a   Johnson, John R ^a   He, Kun ^a   Sridhara, Rajeshwari ^a   Abraham, Sophia ^a   Booth, Brian P ^a   Verbois, Leigh ^a   Morse, David E ^a   Jee, Josephine M ^a   Pope, Sarah ^a   Harapanhalli, Ravi S ^a   Dagher, Ramzi ^a   Farrell, Ann ^a   Justice, Robert ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORINOSTAT;

ADULT; AGED; ALOPECIA; ANOREXIA; CANCER STAGING; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PERIPHERAL EDEMA; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN LYMPHOMA; SKIN MANIFESTATION; T CELL LYMPHOMA; TUMOR GROWTH; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTICARCINOGENIC AGENTS; CATS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DOGS; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, CUTANEOUS; NEOPLASM STAGING; PATIENT SELECTION; PRURITUS; SKIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34247860871     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2672     Document Type: Review

References (6)

1. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000;18:2908-25.
2. American Joint Committee on Cancer. Lymphoid neoplasms. In: American Joint Committee on Cancer cancer staging manual. 6th ed. New York (NY): Springer; 2002. p 393-406.
3. Whitaker SJ, Marsden JR, Spittle M, Jones RR. Joint British Association Of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Derm 2003;149:1095-2007.
4. Trautingera F, Knoblera R, Willemzeb R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eu J Can 2006;42: 1014-30.
5. Rubin E, Agrawal N, Friedman E, et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006;12: 7039-45.
6. Duvic M, Talpur R, Ni X, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood First Edition Paper, prepublished online September 7, 2006; DOI 10.1182/blood-2006-06-025999.